Previous close | 1.9500 |
Open | 1.9600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 185.00 |
Expiry date | 2024-11-15 |
Day's range | 1.9300 - 1.9600 |
Contract range | N/A |
Volume | |
Open interest | N/A |
AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Additionally, a new weight-based oral solution, RINVOQ® LQ (upadacitinib), is now available as an option for these pediatric popu
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē, the Allergan Aesthetics Loyalty Rewards Program. Now, Allē Members can invite their friends and family to join and both parties can receive savings on Allergan Aesthetics products or treatments from brands like BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® Collection of Fillers, SKINVIVE by JUVÉDERM®, CoolSculpting®, SkinMedica®, and DiamondGlow®.
In the most recent trading session, AbbVie (ABBV) closed at $160.19, indicating a -0.65% shift from the previous trading day.